Anti-GD2 ADCC Enhanced Antibody (hu14.18K322A) is an ADCC enhanced antibody produced by our Afuco™ platform. Hu14.18K322A is a monoclonal antibody that is made to bind to cancer cells that have a molecule called GD2 on their surface, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.
Figure 1 Predicted (blue line) and average predicted (gold line) hu14.18K322A serum levels for 11 patients treated at 60 mg/m2 (maximum-tolerated dose) based on two-compartment model.
Blue dots represent observed hu14.18K322A serum levels for representative patient who had median body-surface area among patients treated at 60 mg/m2. Peak serum level on day 4 (immediately after four daily infusions) was greater than that after first infusion on day 1. Elimination of agent after peak on day 1 showed similar pattern to that seen after peak on day 4.
Navid,F.,Sondel,P.M.,Barfield,R.,Shulkin,B.L.,Kaufman,R.A.,Allay,J.A.,& Goldberg, J. (2014).Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14. 18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. Journal of clinical oncology, 32(14), 1445.
Figure 2 Anti-GD2 nanoconstructs are highly specific for GD2 molecules on neuroblastoma cells.
(A) Flow cytometry of anti-GD2-BNF (aGD2-BNF) binding to GD2+ neuroblastoma cells, evidenced by fluorescent antihuman IgG (ahu IgG) antibody (tinted histograms), compared with cells treated with ahu IgG antibody alone (heavy contour clear histograms) or cell autofluorescence (autofluor, light contour clear histograms). (B) Flow cytometry of anti-GD2-BNF or anti-GD2 hu14.18K322A alone binding to GD2+ CHLA-20 cells. (C) Immunofluorescence microscopy (400×) of CHLA-20 detecting human IgG (hu IgG) and nuclear DAPI. Cells were pretreated with BNF, anti-GD2-BNF, hu IgG or medium only (upper four panels). Pretreatment with 1A7 anti-idiotype antibody (aID) or with 14.G2a anti-GD2 antibody (aGD2–14.G2a) prevents binding of anti-GD2-BNF to cells (lower two panels).
Baiu,D.C.,Artz, N.S.,McElreath,M.R.,Menapace,B.D.,Hernando,D. Reeder,S.B.,& Otto,M.(2015).High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. Nanomedicine, 10(19),2973-2988.
Figure 3 Iron is targeted to GD2+ neuroblastoma cells after anti-GD2-Bionized NanoFerrite treatment.
(A) Ferrozine spectrophotometry shows increase in Fe2+/Fe3+ in GD2+ cells after anti-GD2-BNF (aGD2-BNF) treatment when compared with basal iron levels. Averages ± standard error of three to five experiments per cell line p = 0.01). (B) Ferrozine spectrophotometry shows pretreatment of CHLA-20 cells with free hu14.18K322A anti-GD2 antibody (aGD2) prevents cell loading with iron during anti-GD2-BNF treatment. Averages ± standard error of four experiments (p ≤ 0.04; p = 0.01). (C) Microscopy of Perls staining of nonheme iron in CHLA-20 cells after treatment with untargeted BNF, targeted anti-GD2-BNF and free hu14.18K322A anti-GD2 antibody (aGD2) pretreatment before anti-GD2-BNF. Representative of five repeats, 200×.
Baiu,D.C.,Artz, N.S.,McElreath,M.R.,Menapace,B.D.,Hernando,D. Reeder,S.B.,& Otto,M.(2015).High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. Nanomedicine, 10(19),2973-2988.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-770-sdAb | Recombinant Anti-Human GD2 VHH Single Domain Antibody | Neut, ChiP, IP, FUNC | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-731 | Anti-GD2 Recombinant Antibody (Dinutuximab) | Neut, ELISA, IF, IP, FuncS, FC, ICC | IgG1 - kappa |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-L018R | anti-GD2 immunotoxin 14G2a (IgG)-RTA | Cytotoxicity assay, Functional assay |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-304CL | Anti-Human GD2 Recombinant Antibody (hu14.18K322A) | FC, FuncS | Antibody |
PABX-059 | Human Anti-GD2 Recombinant Antibody (PABX-059) | FuncS | IgG1, κ |
PABX-059-F (E) | Human Anti-GD2 Recombinant Antibody; Fab Fragment (PABX-059-F (E)) | FC, ELISA, FuncS | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PABL-100 | Mouse Anti-GD2 Recombinant Antibody (clone 14G2a) | ELISA, WB, FuncS | Mouse IgG |
PABL-101 | Mouse Anti-GD2 Recombinant Antibody (clone 3F8) | FC, ELISA, FuncS | Mouse IgG |
FAMAB-0126YC | Mouse Anti-GD2 Recombinant Antibody (clone 7A4) | ELISA | Mouse IgG3, κ |
HPAB-0701-CN | Human Anti-GD2 Recombinant Antibody (clone AB527) | ELISA, FC, IHC, IF | Human IgM |
HPAB-1030WJ | Human Anti-GD2 Recombinant Antibody (HPAB-1030WJ) | ELISA | Chimeric (mouse/human) IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBL-100 | Mouse Anti-GD2 Recombinant Antibody (clone 14G2a); scFv Fragment | ELISA, WB, FuncS | Mouse scFv |
PSBL-101 | Mouse Anti-GD2 Recombinant Antibody (clone 3F8); scFv Fragment | FC, ELISA, FuncS | Mouse scFv |
MOB-181CQ | Human Anti-GD2 Recombinant Antibody (MOB-181CQ) | ELISA, FC, FuncS | Humanized scFv |
HPAB-1524WJ-S(P) | Human Anti-GD2 Recombinant Antibody; scFv Fragment (clone KM8138) | ELISA, WB | Human scFv |
HPAB-1525WJ-S(P) | Human Anti-GD2 Recombinant Antibody; scFv Fragment (clone KM1138) | ELISA, WB | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-100 | Mouse Anti-GD2 Recombinant Antibody (clone 14G2a); Fab Fragment | ELISA, WB, FuncS | Mouse Fab |
PFBL-101 | Mouse Anti-GD2 Recombinant Antibody (clone 3F8); Fab Fragment | FC, ELISA, FuncS | Mouse Fab |
HPAB-0701-CN-F(E) | Human Anti-GD2 Recombinant Antibody (clone AB527); Fab Fragment | ELISA, FC, IHC, IF | Human Fab |
HPAB-1030WJ-F(E) | Human Anti-GD2 Recombinant Antibody; Fab Fragment (HPAB-1030WJ-F(E)) | ELISA | Chimeric (mouse/human) Fab |
HPAB-1524WJ-F(E) | Human Anti-GD2 Recombinant Antibody; Fab Fragment (clone KM8138) | ELISA, WB | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-074CQ-S(P) | Human Anti-GD2 Recombinant Antibody; scFv Fragment (TAB-074CQ-S(P)) | ELISA, FC | Human scFv |
TAB-075CQ-S(P) | Human Anti-GD2 Recombinant Antibody; scFv Fragment (TAB-075CQ-S(P)) | ELISA, FC | Human scFv |
TAB-076CQ-S(P) | Human Anti-GD2 Recombinant Antibody; scFv Fragment (TAB-076CQ-S(P)) | ELISA, FC | Human scFv |
TAB-077CQ-S(P) | Human Anti-GD2 Recombinant Antibody; scFv Fragment (TAB-077CQ-S(P)) | ELISA, FC | Human scFv |
TAB-078CQ-S(P) | Human Anti-GD2 Recombinant Antibody; scFv Fragment (TAB-078CQ-S(P)) | ELISA, FC | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
NS-029CN | Mouse Anti-GD2 Recombinant Antibody (clone 5F11) | WB | Mouse IgG |
NS-030CN | Mouse Anti-GD2 Recombinant Antibody (clone 3G6) | WB | Mouse IgG |
NS-029CN-F(E) | Mouse Anti-GD2 Recombinant Antibody (clone 5F11); Fab Fragment | WB | Mouse Fab |
NS-030CN-F(E) | Mouse Anti-GD2 Recombinant Antibody (clone 3G6); Fab Fragment | WB | Mouse Fab |
NS-029CN-S(P) | Mouse Anti-GD2 Recombinant Antibody (clone 5F11); scFv Fragment | WB | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-731 | Afuco™ Anti-GD2 ADCC Recombinant Antibody (Dinutuximab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
There are currently no Customer reviews or questions for AFC-291CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.